Ca Bowman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ca Bowman has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
A Eley
Department of Infection and Immunity University of Sheffield Medical School Sheffield UK
1 shared publication- Alan McOwan
Chelsea and Westminster Hospital NHS Foundation Trust, 56 Dean Street, London W1D 6AE, United Kingdom
1 shared publication - Amanda Clarke
Claude Nichol Centre, Royal Surrey Sussex County Hospital, Brighton, UK
1 shared publication - Ann Kathleen Sullivan
Consultant in HIV and Sexual Health Chelsea and Westminster Healthcare NHS Foundation Trust and Imperial College London
1 shared publication - Anthony Nardone
Public Health England, Wellington House, Waterloo Road, London, UK
1 shared publication C Ryan
Sheffield Teaching Hospitals Foundation Trust Royal Hallamshire Hospital Sheffield UK
1 shared publication
Latest Publications
- Open Access
- 24 March 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 163
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of the human immunodeficiency virus (HIV). The PROUD study found that PrEP conferred higher protection than in placebo-controlled trials, reducing HIV incidence by 86 % in a population with seven-fold higher HIV incidence than expected. We present the baseline characteristics of the PROUD study population and place the findings in the context of national sexual health clinic data. The PROUD study was designed to explore the real-world effectiveness of PrEP (tenofovir-emtricitabine) by randomising HIV-negative gay and other men who have sex with men (GMSM) to receive open-label PrEP immediately or after a deferral period of 12 months. At enrolment, participants self-completed two baseline questionnaires collecting information on demographics, sexual behaviour and lifestyle in the last 30 and 90 days. These data were compared to data from HIV-negative GMSM attending sexual health clinics in 2013, collated by Public Health England using the genitourinary medicine clinic activity database (GUMCAD). The median age of participants was 35 (IQR: 29–43). Typically participants were white (81 %), educated at a university level (61 %) and in full-time employment (72 %). Of all participants, 217 (40 %) were born outside the UK. A sexually transmitted infection (STI) was reported to have been diagnosed in the previous 12 months in 330/515 (64 %) and 473/544 (87 %) participants reported ever having being diagnosed with an STI. At enrolment, 47/280 (17 %) participants were diagnosed with an STI. Participants reported a median (IQR) of 10 (5–20) partners in the last 90 days, a median (IQR) of 2 (1–5) were condomless sex acts where the participant was receptive and 2 (1–6) were condomless where the participant was insertive. Post-exposure prophylaxis had been prescribed to 184 (34 %) participants in the past 12 months. The number of STI diagnoses was high compared to those reported in GUMCAD attendees. The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the overall population of GMSM attending sexual health clinics in England. These findings contribute to explaining the extraordinary HIV incidence rate during follow-up and demonstrate that, despite broad eligibility criteria, the population interested in PrEP was highly selective. Current Controlled Trials ISRCTN94465371 . Date of registration: 28 February 2013.
- 24 March 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 163
Open AccessAn analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of the human immunodeficiency virus (HIV). The PROUD study found that PrEP conferred higher protection than in placebo-controlled trials, reducing HIV incidence by 86 % in a population with seven-fold higher HIV incidence than expected. We present the baseline characteristics of the PROUD study population and place the findings in the context of national sexual health clinic data. The PROUD study was designed to explore the real-world effectiveness of PrEP (tenofovir-emtricitabine) by randomising HIV-negative gay and other men who have sex with men (GMSM) to receive open-label PrEP immediately or after a deferral period of 12 months. At enrolment, participants self-completed two baseline questionnaires collecting information on demographics, sexual behaviour and lifestyle in the last 30 and 90 days. These data were compared to data from HIV-negative GMSM attending sexual health clinics in 2013, collated by Public Health England using the genitourinary medicine clinic activity database (GUMCAD). The median age of participants was 35 (IQR: 29–43). Typically participants were white (81 %), educated at a university level (61 %) and in full-time employment (72 %). Of all participants, 217 (40 %) were born outside the UK. A sexually transmitted infection (STI) was reported to have been diagnosed in the previous 12 months in 330/515 (64 %) and 473/544 (87 %) participants reported ever having being diagnosed with an STI. At enrolment, 47/280 (17 %) participants were diagnosed with an STI. Participants reported a median (IQR) of 10 (5–20) partners in the last 90 days, a median (IQR) of 2 (1–5) were condomless sex acts where the participant was receptive and 2 (1–6) were condomless where the participant was insertive. Post-exposure prophylaxis had been prescribed to 184 (34 %) participants in the past 12 months. The number of STI diagnoses was high compared to those reported in GUMCAD attendees. The PROUD study population are at substantially higher risk of acquiring HIV infection sexually than the overall population of GMSM attending sexual health clinics in England. These findings contribute to explaining the extraordinary HIV incidence rate during follow-up and demonstrate that, despite broad eligibility criteria, the population interested in PrEP was highly selective. Current Controlled Trials ISRCTN94465371 . Date of registration: 28 February 2013.
- Open Access
- 22 November 2012
- Published by Wiley in HIV Medicine
- Vol. 14 (2) , 108-114
HIV‐1 co‐receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic
Objectives: The aim of the study was to qualitatively and semiquantitatively characterize the expression of the principal HIV co‐receptors chemokine (C‐C motif) receptor 5 (CCR5) and chemokine (C‐X‐C motif) receptor 4 (CXCR4) on susceptible CD4 T‐helper cell, monocyte/macrophage and Langerhans dendritic cell populations within the cervical epithelia of asymptomatic women attending a genitourinary medicine clinic.Methods: Of 77 asymptomatic women recruited, 35 were excluded: 21 because they were found to have bacterial vaginosis, eight because they were found to have candida and six for other reasons. Cervical cytobrush samples from 11 women with Chlamydia trachomatis infection and 31 women without any detectable genital infection were stained with fluorescently labelled antibodies specific for cell surface CCR5, CXCR4, CD4, CD3, CD1a and CD19 expression, then analysed by flow cytometry.Results: CD4/CD3 T‐helper cells (84%), CD1a Langerhans dendritic cells (75%) and CD4/CD14 monocytes/macrophages (59%) were detected in the samples. CCR5 and CXCR4 HIV co‐receptor expression was observed on 46–86% of the above subsets. CD1a cells exhibited significantly higher CCR5 and CXCR4 positivity and median fluorescence than CD4 cells and higher CXCR4 positivity and median fluorescence than CD14 cells (P < 0.05 or less). Increased detection of CCR5 over CXCR4 was seen in CD14 cells (P < 0.05). No significant differences in CCR5 or CXCR4 expression were found in samples from asymptomatic women with or without chlamydial infection.Conclusions: Co‐receptor expression confirms the potential for CD1a Langerhans cells, monocytes/macrophages and T‐helper cells in the cervix as primary targets for HIV infection. Previously observed selective transmission of CCR5‐tropic isolates cannot be accounted for by a lack of CXCR4‐expressing CD4 cervical immune cells. We were unable to identify any specific impact of chlamydial infection on co‐receptor expression in this study.
- 22 November 2012
- Published by Wiley in HIV Medicine
- Vol. 14 (2) , 108-114
Open AccessHIV‐1 co‐receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic
Objectives: The aim of the study was to qualitatively and semiquantitatively characterize the expression of the principal HIV co‐receptors chemokine (C‐C motif) receptor 5 (CCR5) and chemokine (C‐X‐C motif) receptor 4 (CXCR4) on susceptible CD4 T‐helper cell, monocyte/macrophage and Langerhans dendritic cell populations within the cervical epithelia of asymptomatic women attending a genitourinary medicine clinic.Methods: Of 77 asymptomatic women recruited, 35 were excluded: 21 because they were found to have bacterial vaginosis, eight because they were found to have candida and six for other reasons. Cervical cytobrush samples from 11 women with Chlamydia trachomatis infection and 31 women without any detectable genital infection were stained with fluorescently labelled antibodies specific for cell surface CCR5, CXCR4, CD4, CD3, CD1a and CD19 expression, then analysed by flow cytometry.Results: CD4/CD3 T‐helper cells (84%), CD1a Langerhans dendritic cells (75%) and CD4/CD14 monocytes/macrophages (59%) were detected in the samples. CCR5 and CXCR4 HIV co‐receptor expression was observed on 46–86% of the above subsets. CD1a cells exhibited significantly higher CCR5 and CXCR4 positivity and median fluorescence than CD4 cells and higher CXCR4 positivity and median fluorescence than CD14 cells (P < 0.05 or less). Increased detection of CCR5 over CXCR4 was seen in CD14 cells (P < 0.05). No significant differences in CCR5 or CXCR4 expression were found in samples from asymptomatic women with or without chlamydial infection.Conclusions: Co‐receptor expression confirms the potential for CD1a Langerhans cells, monocytes/macrophages and T‐helper cells in the cervix as primary targets for HIV infection. Previously observed selective transmission of CCR5‐tropic isolates cannot be accounted for by a lack of CXCR4‐expressing CD4 cervical immune cells. We were unable to identify any specific impact of chlamydial infection on co‐receptor expression in this study.